High platelet reactivity tied to ischemic, bleeding outcomes

August 16, 2017

(HealthDay)—There is a strong relationship between high on-clopidogrel platelet reactivity and two-year ischemic and bleeding outcomes after drug-eluting stent implantation, according to a study published online Aug. 2 in JACC: Cardiovascular Interventions.

Thomas D. Stuckey, M.D., from Cone Health in Greensboro, N.C., and colleagues analyzed two-year outcomes in the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents study, which followed 8,582 patients undergoing routine platelet function testing following with drug-eluting (2008 to 2010).

The researchers found that 46.3 percent of patients were on dual antiplatelet therapy at two years without discontinuation. Ninety-two patients (1.07 percent) had definite or probable stent thrombosis at two years. High platelet reactivity on clopidogrel was independently associated with definite or probable stent thrombosis in continuously treated patients (hazard ratio [HR], 2.09; 95 percent confidence interval [CI], 1.29 to 3.82; P = 0.006). Other associations included myocardial infarction (HR, 1.33; 95 percent CI, 1.04 to 1.71; P = 0.02), freedom from clinically relevant bleeding (HR, 0.78; 95 percent CI, 0.64 to 0.94; P < 0.01), and all-cause mortality (adjusted HR, 1.35; 95 percent CI, 1.00 to 1.84, P = 0.05).

"Aspirin hypo-responsiveness in low-risk patients maintained on aspirin monotherapy beyond one year did not predict late events. High reactivity in high-risk maintained on dual antiplatelet therapy was independently associated with outcomes to two years," the authors write. "Future studies evaluating the long-term use of adenosine diphosphate inhibition should incorporate individualized patient selection to optimize the trade-off between ischemic event reduction and bleeding."

Several authors disclosed financial ties to medical device and pharmaceutical companies, several of which funded the study.

Explore further: 1-year results of ADAPT-DES trial published in The Lancet

More information: Abstract/ Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

1-year results of ADAPT-DES trial published in The Lancet

July 26, 2013
Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less ...

Study: AHA guidelines to treating patients with coronary artery disease

June 27, 2017
The most recent dual antiplatelet guidelines from the American Heart Association and the American College of Cardiology encourage healthcare providers to take a customized approach to treating patients with coronary artery ...

Risk up for triple Tx versus DAPT in DES implantation with A-fib

May 23, 2017
(HealthDay)—For patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES), atrial fibrillation (AF) is associated with increased risks, with no benefit and higher risk seen for triple therapy ...

Anemia independently linked to high platelet reactivity in PCI

June 9, 2016
(HealthDay)—Anemia is independently associated with high platelet reactivity (HPR) and is associated with all-cause mortality and major bleeding after percutaneous coronary intervention with drug-eluting stents, according ...

30-day results of ADAPT-DES registry reported at TCT 2011

November 9, 2011
The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis ...

Low responsiveness to clopidogrel predicts stent thrombosis, heart attack: But is not directly linked to death

October 25, 2012
Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible heart attack; conversely, patients with higher ...

Recommended for you

Eating yogurt may reduce cardiovascular disease risk

February 15, 2018
A new study in the American Journal of Hypertension, published by Oxford University Press, suggests that higher yogurt intake is associated with lower cardiovascular disease risk among hypertensive men and women.

Newly discovered gene may protect against heart disease

February 14, 2018
Scientists have identified a gene that may play a protective role in preventing heart disease. Their research revealed that the gene, called MeXis, acts within key cells inside clogged arteries to help remove excess cholesterol ...

Blood thinners may raise stroke risk in over-65s with kidney disease

February 14, 2018
People over 65 years old may be increasing their stroke risk by taking anticoagulants for an irregular heartbeat if they also have chronic kidney disease, finds a new study led by UCL, St George's, University of London and ...

Cardiac macrophages found to contribute to a currently untreatable type of heart failure

February 14, 2018
A team of Massachusetts General Hospital (MGH) investigators has discovered, for the first time, that the immune cells called macrophages contribute to a type of heart failure for which there currently is no effective treatment. ...

Study maps molecular mechanisms crucial for new approach to heart disease therapy

February 13, 2018
Creating new healthy heart muscle cells within a patient's own ailing heart. This is how scientists hope to reverse heart disease one day. Today, a new study led by UNC-Chapel Hill researchers reveals key molecular details ...

Congenital heart defects linked to increased risk of dementia

February 13, 2018
Being born with a heart defect may raise the odds of later developing dementia, especially early-onset dementia, a new study finds.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.